Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

Recruiting now · Phase 2

Conditions studied: Classical Hodgkin Lymphoma

In brief

The aim of the trial is to establish an individualized first-line treatment incorporating checkpoint inhibition for early-stage unfavorable cHL, which is effective and well tolerated.

Key facts

Study ID

NCT04837859

Run by

University of Cologne

People needed

120

Starts

2024-05-24

Expected to finish

2028-05-01

Last updated by the study team

2024-07-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-60 for the main trial cohort
• Age ≥ 61 years and eligible for AVD as determined by CIRS-G score and investigator for the exploratory cohort
• First diagnosis of treatment-naïve cHL
• Early-stage unfavorable disease (i.e. stage IA, IB and IIA with risk factors a-d, stage IIB with risk factors c-d):
• large mediastinal mass
• extranodal lesion(s)
• elevated erythrocyte sedimentation rate
• ≥ 3 nodal areas

You may not qualify if…

• Presence of nodular-lymphocyte predominant Hodgkin lymphoma, grey-zone lymphoma and/or central nervous system involvement of lymphoma

Where it is running

• 1st Department of Medicine, Cologne University Hospital — Cologne, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.